Skip to main content
SpringerLink
Log in

Natural history and therapy of AL cardiac amyloidosis

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

The natural history of immunoglobulin light chain associated amyloidosis (AL) is determined by the extent of cardiac involvement. Patients with cardiac AL and symptomatic heart failure have a median survival of approximately six months without successful treatment of the underlying plasma cell disorder The outcome in cardiac AL is determined by both the severity of cardiac involvement and the response to treatment. Staging systems using cardiac biomarkers, including NT- proBNP and troponin, have been found to be powerful predictors of prognosis and are used to guide treatment. Arrhythmias are common in cardiac AL and may lead to acute hemodynamic compromise. Sudden cardiac death, often due to pulseless electrical activity, is an important cause of early mortality. Supportive therapy for heart failure is usually limited to diuretics. Beta-blockers, ACE-inhibitors, and angiotensin receptor blockers are poorly tolerated in cardiac AL and should be avoided. Cardiac transplantation is controversial and reserved for highly selected patients with limited extracardiac involvement. The primary target of treatment in cardiac AL is obliteration of the plasma cell clone, using chemotherapy alone or combined with autologous stem cell transplantation. Despite the risk of early mortality, overall survival has improved with advances in disease modifying therapy. Earlier diagnosis and treatment of cardiac AL is crucial to improving survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Kyle R, Linos A, Beard C, Linke R, Gertz M, O’Fallon W et al (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79(7):1817–1822

  2. Palladini G (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30:4541–4549

    Article  CAS  PubMed  Google Scholar 

  3. Kumar SK (2011) Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 86:12–18

    Article  PubMed Central  PubMed  Google Scholar 

  4. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al (2004) Serum cardiac troponins and N-Terminal Pro-Brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22(18):3751–3757

    Article  CAS  PubMed  Google Scholar 

  5. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al (2004) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104(6):1881–1887

  6. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989–995

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N et al (2013) Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 48(4):557–561

    Article  CAS  PubMed  Google Scholar 

  8. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121(17):3420–3427

  9. Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D et al (2010) Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 116(14):2455–2461

  10. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G et al (2010) The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116:3426–3430

  11. Dieplinger B, Egger M, Haltmayer M, Kleber ME, Scharnagl H, Silbernagel G et al (2014) Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem 60(3):530–540

    Article  CAS  PubMed  Google Scholar 

  12. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C et al (2008) Complementary roles for biomarkers of biomechanical strain ST2 and N-Terminal prohormone B-Type natriuretic peptide in patients with ST-Elevation myocardial infarction. Circulation 117(15):1936–1944

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, Squire IB et al (2013) Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol 167(5):2182–2188

    Article  PubMed  Google Scholar 

  14. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS et al (2012) Role of ST2 in Non-ST-Elevation acute coronary syndrome in the MERLIN-TIMI 36 Trial. Clin Chem 58(1):257–266

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Wang Y-C, Yu C-C, Chiu F-C, Tsai C-T, Lai L-P, Hwang J-J et al (2013) Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Cardiac Fail 19(3):163–168

    Article  CAS  Google Scholar 

  16. Lupón J, de Antonio M, Galán A, Vila J, Zamora E, Urrutia A et al (2013) Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc 88(3):234–243

    Article  PubMed  Google Scholar 

  17. Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola V-P et al (2013) Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the multinational observational cohort on acute heart failure (MOCA) study. Int J Cardiol 168(3):2186–2194

    Article  PubMed  Google Scholar 

  18. van Kimmenade RR, Januzzi JL (2012) Emerging biomarkers in heart failure. Clin Chem 58(1):127–138

    Article  PubMed  Google Scholar 

  19. Dispenzieri AS, Amy K., Kumar SK, Gertz MA, Lacy MQ, Buadi F, Hayman SR, et al. (2014) Soluble ST2 (sST2) is a novel valuable prognostic marker among patients with immunoglobulin light chain (AL) Amyloidosis [abstract OP-33]. Presented at the XIVth international symposium on amyloidosis

  20. Falk RH, Rubinow A, Cohen AS (1984) Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 3(1):107–113

    Article  CAS  PubMed  Google Scholar 

  21. Wright BLC, Grace AA, Goodman HJB (2006) Implantation of a cardioverter-defibrillator in a patient with cardiac amyloidosis. Nat Clin Pract Cardiovasc Med 3(2):110–114

    Article  PubMed  Google Scholar 

  22. Hess EP, White RD (2004) Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients. Resuscitation 60(1):105–111

    Article  PubMed  Google Scholar 

  23. Mercando AD, Furman S, Johnston D, Frame R, Brodman R, Kim SG et al (1988) Survival of patients with the automatic implantable cardioverter defibrillator. Pacing Clin Electrophysiol 11(11):2059–2063

    Article  CAS  PubMed  Google Scholar 

  24. Lin G, Dispenzieri A, Brady PA (2010) Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. Eur Heart J 31(12):1538

    Article  PubMed  Google Scholar 

  25. Dhoble A, Khasnis A, Olomu A, Thakur R (2009) Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol 32(8):E63–E65

    Article  PubMed  Google Scholar 

  26. Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 24(7):793–798

    Article  PubMed  Google Scholar 

  27. Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S et al (2014) Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm Off J Heart Rhythm Soc 11(1):158

    Article  Google Scholar 

  28. McCarthy IRE, Kasper EK (1998) A review of the amyloidoses that infiltrate the heart. Clin Cardiol 21(8):547–552

    Article  PubMed  Google Scholar 

  29. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M (2005) Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 95(4):535–537

    Article  PubMed  Google Scholar 

  30. Cassidy JT (1961) Cardiac amyloidosis. two cases with digitalis sensitivity. Ann Intern Med 55(6):989–994

    Article  CAS  PubMed  Google Scholar 

  31. Rubinow A, Skinner M, Cohen AS (1981) Digoxin sensitivity in amyloid cardiomyopathy. Circulation 63(6):1285–1288

    Article  CAS  PubMed  Google Scholar 

  32. Dubrey S, Pollak A, Skinner M, Falk RH (1995) Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 74(5):541–544

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S (2007) Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 50(22):2101–2110

    Article  CAS  PubMed  Google Scholar 

  34. Feng D, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119(18):2490–2497

    Article  CAS  PubMed  Google Scholar 

  35. Modesto KM, Dispenzieri A, Cauduro SA, Lacy M, Khandheria BK, Pellikka PA et al (2005) Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J 26(2):173–179

    Article  PubMed  Google Scholar 

  36. Mathew VMD, Olson LJMD, Gertz MAMD, Hayes DLMD (1997) Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol 80(11):1491–1492

  37. Epstein AE, DiMarco JP, Ellenbogen KA, Estes IIINAM, Freedman RA, Gettes LS et al (2008) ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalitiesa report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and Antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 51(21):e1–e62

    Article  PubMed  Google Scholar 

  38. Maleszewski JJ (2013) Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol 22:189–194

  39. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A (2009) Classification of amyloidosis by laser microdissection and mass spectrometry–based proteomic analysis in clinical biopsy specimens. Blood 114:4957–4959

  40. Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112(13):2047–2060

    Article  PubMed  Google Scholar 

  41. DiNicolantonio JJ (2012) Should torsemide be the loop diuretic of choice in systolic heart failure? Futur Cardiol 8(5):707–728

    Article  CAS  Google Scholar 

  42. Shah KB, Inoue Y, Mehra MR (2006) Amyloidosis and the heart: a comprehensive review. Arch Intern Med 166(17):1805–1813

    Article  CAS  PubMed  Google Scholar 

  43. Gertz M, Falk R, Skinner M, Cohen A, Kyle R (1985) Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 55:1645

    Article  CAS  PubMed  Google Scholar 

  44. Griffiths B, Hughes P, Dowdle R, Stephens M (1982) Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax 37(9):711

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Pollak A, Falk RH (1993) Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 104(2):618–620

    Article  CAS  PubMed  Google Scholar 

  46. Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM et al (2003) Persistent Pleural Effusions in Primary Systemic AmyloidosisEtiology and Prognosis. Chest J 124(3):969–977

    Article  Google Scholar 

  47. De Lorenzi ED, Giorgetti S, Grossi S, Merlini G, Caccialanza G, Bellotti V (2004) Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a “protein misfolding disease”. Curr Med Chem 11(8):1065–1084

    Article  PubMed  Google Scholar 

  48. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM et al (2003) High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 33(4):381–388

    Article  Google Scholar 

  49. Gertz MA, Lacy MQ, Dispenzieri A (2004) Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 18(1):17–37

    Article  PubMed  Google Scholar 

  50. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F et al (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103(8):2936–2938

  51. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Berk JL, Dember LM et al (2002) Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 117(4):886–889

    Article  CAS  PubMed  Google Scholar 

  52. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH et al (2003) Tolerability and efficacy of thalidomide for the treatment of patients with light chain–associated (AL) amyloidosis. Clin lymphoma 3(4):241–246

    Article  CAS  PubMed  Google Scholar 

  53. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al (2004) High-Dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140(2):85–93

    Article  CAS  PubMed  Google Scholar 

  54. Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN (2006) Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 134(4):417–425

    Article  PubMed  Google Scholar 

  55. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB et al (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122(1):78–84

    Article  CAS  PubMed  Google Scholar 

  56. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107(10):3854–3858

  57. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336(17):1202–1207

    Article  CAS  PubMed  Google Scholar 

  58. Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F et al (2008) Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 49(1):36–41

    Article  CAS  PubMed  Google Scholar 

  59. Saba N, Sutton D, Ross H, Siu S, Crump R, Keating A et al (1999) High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 24(8):853–855

    Article  CAS  PubMed  Google Scholar 

  60. Comenzo RL, Gertz MA (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99(12):4276–4282

    Article  CAS  PubMed  Google Scholar 

  61. Moreau P (1999) Autologous stem cell transplantation for AL amyloidosis: a standard therapy? Leukemia 13(12):1929–1931

    Article  CAS  PubMed  Google Scholar 

  62. Kpodonu J, Massad MG, Caines A, Geha AS (2005) Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 24(11):1763–1765

    Article  PubMed  Google Scholar 

  63. Dubrey SW, Burke MM, Hawkins PN, Banner NR (2004) Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 23(10):1142–1153

    Article  PubMed  Google Scholar 

  64. Gray Gilstrap L, Niehaus E, Malhotra R, Ton VK, Watts J, Seldin DC et al (2014) Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant 33(2):149–156

    Article  PubMed  Google Scholar 

  65. Varr BC, Liedtke M, Arai S, Lafayette RA, Schrier SL, Witteles RM (2012) Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies. J Heart Lung Transplant 31(3):325–331

    Article  PubMed  Google Scholar 

  66. Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J et al (2006) Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 107(3):1227–1229

    Article  CAS  PubMed  Google Scholar 

  67. Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M et al (2007) Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 83(5):539–545

    Article  PubMed  Google Scholar 

  68. Dey B, Chung S, Spitzer T, Zheng H, Macgillivray T, Seldin D et al (2010) Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 90(8):905–911

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Kristen AV, Sack F-U, Schonland SO, Hegenbart U, Helmke BM, Koch A et al (2009) Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail 11(10):1014–1020

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

    Martha Grogan

  2. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

    Angela Dispenzieri

Authors
  1. Martha Grogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angela Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martha Grogan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grogan, M., Dispenzieri, A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev 20, 155–162 (2015). https://doi.org/10.1007/s10741-014-9464-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-014-9464-5

Keywords

Search

Navigation